Drug Trial Radar · NCT07406334
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
46
Actual
Start
May 15, 2026
Primary completion
Feb 22, 2027
Study completion Feb 22, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 months, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the safety and reactogenicity of a single dose of the new pneumococcal vaccine (called Pn-MAPS30plus) in toddlers who have previously completed a two-dose primary vaccination series with PCV used in local immunization program. PCV20 will be used as a comparator for this study.
Conditions
- Pneumonia, Bacterial
Interventions
Pn-MAPS30plusBiological
Pn-MAPS30plus vaccine will be administered intramuscularly.
PCV20Combination product
PCV20 vaccine will be administered intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Solicited Administration site Adverse Events (AEs)Time frame: Day 1 to Day 7
- Number of Participants with Solicited Systemic Adverse Events (AEs)Time frame: Day 1 to Day 7
- Number of Participants with Unsolicited AEsTime frame: Day 1 to Day 30
- Number of Participants with Serious AEs (SAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to WithdrawalTime frame: Day 1 up to trial end (Month 6)
- Number of Participants with Hematological and Biochemical Laboratory AbnormalitiesTime frame: On Day 8 compared to Day 1 (pre-vaccination)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Pretoria, South Africa
GSK Investigational Site
Soweto, Johannesburg, Gauteng, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.